Patients were randomized to receive nintedanib ( @ mg twice daily ) , afatinib ( @ mg once daily -LSB- q.d. -RSB- ) , or alternating sequential @-day nintedanib ( @ mg twice daily ) and afatinib ( @ mg q.d. -LSB- Combi@ -RSB- ) , which was reduced to @ mg q.d. ( Combi@ ) due to adverse events .